

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

{Cardboard box}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Marbosyva 100 mg/ml solution for injection for cattle and pigs  
Marbofloxacin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains:  
Marbofloxacin 100 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle and pigs (sows).

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: Intramuscular, subcutaneous or intravenous use.

Pigs (sows): Intramuscular use.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**Withdrawal periods:**

**Cattle:**

Intramuscular use (8 mg/kg single dose):

Meat and offal: 3 days

Milk: 72 hours

Intramuscular or subcutaneous use (2 mg/kg single daily injection, for 3-5 days):

Meat and offal: 6 days

Milk: 36 hours

**Pigs (sows):**

Intramuscular use:

Meat and offal: 4 days

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use by...

Shelf-life after first opening the container: 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

Administration by a veterinary surgeon or under their direct responsibility.

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Laboratorios SYVA, S.A.U.

Avda. Párroco Pablo Díez, 49-57

24010 – León

SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 31592/4006

**17. MANUFACTURER’S BATCH NUMBER**

Batch {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

{50 ml vial  
100 ml vial  
250 ml vial}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Marbosyva 100 mg/ml solution for injection for cattle and pigs  
Marbofloxacin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains:  
Marbofloxacin 100 mg/ml

**3. PHARMACEUTICAL FORM**

**4. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle and pigs (sows).

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: Intramuscular, subcutaneous or intravenous use.

Pigs (sows): Intramuscular use.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**Withdrawal periods:**

**Cattle:**

Intramuscular use (8 mg/kg single dose):

Meat and offal: 3 days

Milk: 72 hours

Intramuscular or subcutaneous use (2 mg/kg single daily injection, for 3-5 days):

Meat and offal: 6 days

Milk: 36 hours

**Pigs (sows):**

Intramuscular use:

Meat and offal: 4 days

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use by...

Shelf-life after first opening the container: 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

Administration by a veterinary surgeon or under their direct responsibility.

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Laboratorios SYVA, S.A.U.

Avda. Párroco Pablo Díez, 49-57

24010 – León

SPAIN

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 31592/4006

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**

**Marbosyva 100 mg/ml solution for injection for cattle and pigs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

LABORATORIOS SYVA, S.A.U.  
Av. Párroco Pablo Díez, 49-57  
24010 LEÓN  
SPAIN

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Marbosyva 100 mg/ml solution for injection for cattle and pigs

Marbofloxacin

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each ml contains:

**Active substance:**

Marbofloxacin ..... 100 mg/ml

**Excipients:**

Metacresol ..... 2 mg/ml  
Monothioglycerol ..... 1 mg/ml  
Disodium edetate..... 0.1 mg/ml

Solution for injection

Clear, yellowish solution

**4. INDICATION(S)**

In cattle:

- Treatment of respiratory infections caused by marbofloxacin-susceptible strains of *Histophilus somni*, *Mannheimia haemolytica*, *Pasteurella multocida* and *Mycoplasma bovis*.
- Treatment of acute forms of mastitis induced by marbofloxacin-susceptible *Escherichia coli* strains, during lactation.

In pigs (sows):

- Treatment of Postpartum Dysgalactiae Syndrome, PDS (Metritis Mastitis Agalactia Syndrome) caused by marbofloxacin-susceptible bacterial strains.

## 5. CONTRAINDICATIONS

Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).

Do not use in cases of hypersensitivity to the active substance, to any other quinolone or to any of the excipients.

## 6. ADVERSE REACTIONS

In very rare cases:

- Transitory inflammatory lesions can occur at the injection site, without clinical impact, when administered via the intramuscular or subcutaneous route.
- Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site, and inflammatory lesions, which may persist, for at least 12 days after injection.
- However, in cattle, the subcutaneous route was shown to be better tolerated locally than the intramuscular route. Therefore, the subcutaneous route is recommended in heavy cattle.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}.

## 7. TARGET SPECIES

Cattle and pigs (sows)

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

### Cattle:

#### **Respiratory infections:**

The recommended dosage is 8 mg marbofloxacin/kg body weight (2 ml veterinary medicinal product/25 kg body weight) in a single injection by the intramuscular route. If the volume to be injected is more than 20 ml, it should be divided between two or more injection sites.

In cases of respiratory infections caused by *Mycoplasma bovis*, the recommended dose is 2 mg marbofloxacin/kg body weight (1 ml veterinary medicinal product/50 kg body weight), in a single daily injection for 3 to 5 consecutive days, by the

intramuscular or subcutaneous route. The first injection may be given by the intravenous route.

**Acute mastitis:**

The recommended dosage is 2 mg marbofloxacin/kg body weight (1 ml veterinary medicinal product/50 kg body weight) in a single daily injection, by the subcutaneous or intramuscular route, for 3 consecutive days. The first injection may be given by the intravenous route.

**Pigs (sows):**

The recommended dosage is 2 mg marbofloxacin/kg bodyweight (1 ml veterinary medicinal product/50 kg body weight) in a single daily injection by the intramuscular route, for 3 consecutive days.

In cattle and pigs, the preferred injection site is the neck area.

To ensure a correct dosage bodyweight should be determined as accurately as possible to avoid underdosing.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

As the vial cannot be broached more than 50 times, the user should choose the most appropriate vial size according to the target species to treat.

**9. ADVICE ON CORRECT ADMINISTRATION**

**10. WITHDRAWAL PERIOD(S)**

**Cattle:**

Intramuscular use (8 mg/kg single dose):

Meat and offal: 3 days

Milk: 72 hours

Intramuscular or subcutaneous use (2 mg/kg single daily injection, for 3-5 days):

Meat and offal: 6 days

Milk: 36 hours

**Pigs (sows):**

Intramuscular use:

Meat and offal: 4 days

**11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Shelf life after first opening the container: 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals

Official and local antimicrobial policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Whenever possible, fluoroquinolones should only be used based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

The efficacy data showed that the product has insufficient efficacy for the treatment of acute forms of mastitis induced by gram-positive bacteria.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to (fluoro)quinolones should avoid contact with the veterinary medicinal product.

Care should be taken to avoid accidental self injection, it can induce a slight irritation.

In case of accidental self injection, seek medical advice and show the package leaflet or the label to the physician.

In case of contact with skin or eyes, rinse with plenty of water.

Wash hands after use.

### Use during pregnancy, lactation or lay:

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.

### Dose of 2 mg marbofloxacin/kg bodyweight

Can be used during pregnancy and lactation.

The safety of the veterinary medicinal product has been established in cows during gestation and suckling pigs and calves when used in cows and sows.

### Dose of 8 mg marbofloxacin/kg bodyweight

The safety of the veterinary medicinal product has not been established in pregnant cows or in suckling calves when used in cows. Therefore, this dose regimen should be used only according to the benefit/risk assessment by the responsible veterinarian.

In case of use in lactating cow, see section 10.

### Overdose

No sign of overdosage has been observed with the product after administration of 3 times the recommended dose.

Signs such as neurological disorders may occur when the dose is exceeded. Do not exceed the recommended dose. These signs would have to be treated symptomatically.

### Major Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary products.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

{DD/MM/YYYY}

## **15. OTHER INFORMATION**

Cardboard box containing one Type II amber glass vial of 50 ml, 100 ml or 250 ml, with a Type I bromobutyl rubber stopper and an aluminium cap.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Veterinary use. Under veterinary prescription.

Administration under control or supervision of a veterinary surgeon.



Approved 21 February 2018